Signaling via a CD28/CD40 chimeric costimulatory antigen receptor (CoStARTM), targeting folate receptor alpha, enhances T cell activity and augments tumor reactivity of tumor infiltrating lymphocytes. This evidence concerns the gene CD28 and neoplasm.